Johnson & Johnson's Janssen unit is teaming up with nonprofit JDRF to develop new diagnostic approaches for Type 1 diabetes, aiming to identify the disease earlier and curb its progression.
A group of researchers at Cornell says it engineered a human probiotic that also had a similar effect in controlling blood glucose levels in rat models for the disease. And a biotech has already snagged the license on this work as they set the stage to try it in humans.
A transatlantic team of researchers says that they have identified a new pathway in the brain that plays a critical role in signaling hypoglycemia. And they add that it's a solid target for drug researchers working in the blockbuster field.
Shanghai's Hua Medicine hauled in a $25 million B round to advance its work on a new treatment for diabetes, bringing in investors from the U.S. and China as it moves toward late-stage development.
Investigators at Baylor College of Medicine say that new animal research indicates that a certain type of T cell found in the immune system could be a good target for drug developers spotlighting Type 2 diabetes triggered by obesity as well as insulin resistance.
Roche's Lucentis may now have a bigger jump on Eylea in diabetic retinopathy. The Swiss drugmaker's Genentech unit won the FDA's "breakthrough" designation for that indication on Monday. And Lucentis was already on the FDA's priority review track, with a decision date in February.
Brown fat is once again providing clues in how to treat metabolic disorders like diabetes. A group of investigators at the University of Michigan followed up on earlier studies that have examined the role of brown fat in burning calories. Their work led them to NRG4, a hormone secreted by brown fat that may play a role as a messenger with the liver in regulating the conversion of sugar into fat, according to the university.
Just a few weeks after claiming success with a pair of late-stage studies of its prolonged dosing approach to diabetes, Boston-based Intarcia has followed up with a billion dollar-plus sized commercialization deal for ex-U.S. and Japan commercial rights with France's Servier.
For another clue to the unrest on Sanofi's board, take a look at the third-quarter earnings report. There's not much red ink on the page, that's true: Sales are up 4%. Earnings up 8%. CEO Chris Viehbacher's growth platforms surged by 10%. The trouble lies in Viehbacher's canned quote.
Virginia's Health Diagnostic Laboratory and the University of Utah are zeroing in on fasting levels of simple blood biomarkers that may enable quicker diagnosis of diabetes risks than current standards of care.